First Time Loading...

TCR2 Therapeutics Inc
NASDAQ:TCRR

Watchlist Manager
TCR2 Therapeutics Inc Logo
TCR2 Therapeutics Inc
NASDAQ:TCRR
Watchlist
Price: 1.48 USD Market Closed
Updated: May 8, 2024

TCR2 Therapeutics Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

TCR2 Therapeutics Inc
Net Income (Common) Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
TCR2 Therapeutics Inc
NASDAQ:TCRR
Net Income (Common)
-$151.8m
CAGR 3-Years
-16%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$4.8B
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$484m
CAGR 3-Years
17%
CAGR 5-Years
-39%
CAGR 10-Years
-20%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.6B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is TCR2 Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-151.8m USD

Based on the financial report for Dec 31, 2022, TCR2 Therapeutics Inc's Net Income (Common) amounts to -151.8m USD.

What is TCR2 Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-59%

Over the last year, the Net Income (Common) growth was -52%. The average annual Net Income (Common) growth rates for TCR2 Therapeutics Inc have been -16% over the past three years , -59% over the past five years .